Capricor Therapeutics Announces 24-Month Results From Ongoing HOPE-2 Open Label Extension Study Of CAP-1002 In Duchenne Muscular Dystrophy
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics has announced 24-month results from its ongoing HOPE-2 open label extension study of CAP-1002 in Duchenne Muscular Dystrophy (DMD). The results show improvements in Left Ventricular Ejection Fraction (LVEF) for the majority of patients, suggesting preservation of cardiac function. The results also continue to show long-term benefit in skeletal muscle function and suggest potential disease attenuation in DMD. The results will be presented at the PPMD Annual Conference.
June 30, 2023 | 1:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive results from Capricor Therapeutics' HOPE-2 study of CAP-1002 in DMD could potentially boost the company's stock in the short term.
The positive results from the HOPE-2 study suggest that CAP-1002 could be an effective treatment for DMD. This could potentially lead to increased demand for the drug, which could boost Capricor's revenues and, in turn, its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100